Duac
DrugClindamycon and benzoyl peroxide topical gel once a day for 12 weeks
NCT Number: NCT00841776
The purpose of the study is to determine the development of microbial resistance when using one of two topical acne therapies for the treatment of facial acne vulgaris.
Looking for future studies?
Notify Me12 year and older
All sexes
Interventional
Phase 4
Dermatology Specialists, PSC, Louisville, Kentucky, United States
To investigate the development of microbial resistance when using one of two topical acne therapies for the treatment of moderate to moderately severe facial acne vulgaris. Clinical efficacy and tolerability will be assessed.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Clindamycon and benzoyl peroxide topical gel once a day for 12 weeks
Clindamycin and tretinoin gel once a day for 12 weeks.
Time frame: Baseline, Weeks 2, 4, 8, 12, & 16
Median change in total colony forming units of propionibacterium acne (P.acne) will be counted.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16
Median change in total colony forming units of clindamycin resistant p. acne.
Time frame: Baseline, Weeks 2, 4, 8, 12, and 16
Total colony forming units of erythromycin-resistant p. acnes.
Time frame: Baseline, Weeks 2, 4, 8, 12, and 16
Median Change in Total Acne Lesions
Time frame: Baseline, Weeks 2, 4, 8, 12, and 16
Median Change in Inflammatory Acne Lesion Counts
Time frame: Baseline, Weeks 2, 4, 8, 12, and 16
Median Change in Noninflammaotry Acne Counts
Stiefel, a GSK Company
Industry
Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Moderate to Moderately Severe Facial Acne Vulgaris
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07572331
Acne, Acne Vulgaris
Beverly, Massachusetts, United States
View Trial DetailsNCT07076784
Acne, Acne Scars
Seoul, South Korea
View Trial DetailsNCT07428954
Acne, Acne Vulgaris
Bilbao, Basque Country, Spain
View Trial DetailsNCT07428915
Acne, Acne Conglobata
Bilbao, Basque Country, Spain
View Trial Details